Citius Oncology (CTOR) said Monday it has signed an agreement naming McKesson (MCK) as an authorized US distributor of Lymphir, an immunotherapy for adults with relapsed or refractory stage I to III cutaneous T-cell lymphoma.

Financial details were not provided.

McKesson joins two other distributors, completing the core US distribution network for Lymphir, Citius said.

Lymphir has been approved by the US Food and Drug Administration, with a commercial launch planned for Q4, according to the company.

Citius shares were up more than 5% in early trading Monday, and McKesson stock was slightly higher.